A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease
A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease
复制标题
DOI：
10.1111/apt.12339
复制
发表时间：
2013-07-01
影响因子：
7.6
通讯作者：
Orchard, T.
中科院分区：
文献类型：
--
作者：
Lindsay, J. O.;Chipperfield, R.;Orchard, T.
Background Crohn's disease (CD) places a substantial burden on healthcare systems, with the majority of costs arising from hospitalisation and surgery. Aim To evaluate the real-world' clinical effectiveness, impact on healthcare utilisation and cost of infliximab for the treatment of CD in UK practice. Methods A non-interventional, retrospective analysis of medical records from patients with CD treated with infliximab at 18 hospital centres across the UK. The primary objective was to compare cumulative clinical outcomes and healthcare resource utilisation for the 0- to 24-month post-infliximab period with the 12months preceding infliximab treatment. Predefined outcomes included the number of elective surgical procedures, hospitalisations and healthcare provider consultations. Costs associated with healthcare utilisation were collected from the perspective of the UK National Health Service (NHS). Results The study involved 380 patients. Infliximab significantly reduced the mean number of elective (from 0.18 to 0.11; P=0.0035) and non-elective (from 0.46 to 0.29; P
